Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
Jun Gong, MD, gives his perspective on neoadjuvant chemotherapy in elderly patients with muscle-invasive bladder cancer.
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
Focused discussion on the duration of maintenance avelumab for metastatic urothelial carcinoma and considerations for switching therapy.
A brief review of whether FGFR status in metastatic urothelial carcinoma should impact treatment approaches.
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
Research suggests age-standardized incidence and death rates for patients with bladder cancer decreased globally between 1990 and 2019.
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.